MedImmune and Micromet AG, a wholly owned subsidiary of Micromet, Inc., will receive a milestone payment from MedImmune triggered by the IND filing. Micromet’s Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types. All-Cash Transaction Values Micromet at. The initial development plan contemplates EUR 25 million in funding of Micromet R&D activities if two BiTE antibodies are advanced to IND.
|Published (Last):||19 August 2010|
|PDF File Size:||10.87 Mb|
|ePub File Size:||17.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
The candidate is in mid-stage development. Through the killing process, T cells start to proliferate, which leads to an microomet number of T cells at the site of attack. Micrpmet note that the most promising candidate at Micromet is blinatumomab MTalso being co-developed with MedImmune, for the treatment of acute lymphoblastic leukemia ALLa type of blood cancer. Now you can 3D print glass 23 Apr, Two product candidates are currently in clinical trials.
New process to help desalinate water faster, cheaper 30 Aug, Leave a Reply Cancel reply Your email address will not be published. This is micormet second highest pollution level of jnd year. EPFO may give your money more stock play next year Updated: MedImmune made a milestone payment to Micromet following the submission of the IND for MT, which demonstrated anti-tumor growth features in pre-clinical studies. Delhi records year’s second highest pollution level 23 Dec, Prior to joining Cytogen, Mr.
Dental treatments burning a hole in your pocket? National Entrepreneurship Awards This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
Micromet could also earn up to mcromet royalties on worldwide net sales.
Micromet Announces Solid Tumor BiTE Antibody Collaboration with Amgen | FierceBiotech
TERI 17 Apr, Have you read these stories? Amgen will lead indd clinical development, manufacturing, and commercialization of any products resulting from the collaboration. About Zacks Investment Research Articles.
Micromet will leverage its BiTE micromett, and Amgen will have the right to pursue development and commercialization of compounds for up to two mmicromet these targets. New York, Aug 30 IANS In a finding that could make the process of removing salt from seawater easier, faster and cheaper than ever before, researchers have discovered that carbon nanotubes of a certain size act as the perfect filter for salt — the most abundant water contaminant. In Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions.
Schnittker has extensive experience in the financial management of publicly listed and privately held biotechnology and pharmaceutical companies.
Bio-weapon experts aren’t buying the Tesla Model X’s bio-weapon defense mode 1 Oct, The new biogenic products can rebuild teeth and cure cavities without costly and uncomfortable treatments. The War on Food.
The Peaks and Valleys. The move from the current Carlsbad headquarters in California to the East Coast will be completed during the 4 th quarter. This natural product helps rebuild tooth enamel 13 Apr, All News Videos Photos.
Amgen Pays $10M Up Front in Cancer Deal with Micromet
In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations. In addition to the finance, business development and legal functions, Micromet is planning to expand the US headquarters by adding a development team for US clinical trials and regulatory interactions with the FDA.
Schnittker received his B.
TomorrowMakers Let’s get smarter about money. Micromet is responsible for the development and commercialization of the candidate inEurope.
Good News for Micromet
CSR Compendium Touching lives of many. These factors and others are more fully discussed knd our periodic reports and other filings with the SEC. Following the acceptance of the application by the FDA, MT is expected to move into human studies in the first half of Currently, we have a Neutral recommendation on Micromet.